LOXL2—A New Target in Antifibrogenic Therapy?
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resolution. Therefore, the study of the molecular mechanisms involved in the pathogenesis of liver fibrosis is critical for the development of future antifibrotic therapies. The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2). These changes in the composition of the extracellular matrix components alter their interaction with cell adhesion molecules, influencing the modulation of cell functions (growth, migration, and gene expression). Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors. The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action. The research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix. LOXL2 inhibition can decrease cell numbers, proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis. The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment. The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs. The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“LOX enzymes are widely used to block collagen crosslinking in various preclinical settings [130, 131].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [131]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309 · cited 2×
“Expression levels of LOXL2 were markedly increased in matched adjacent non-tumor tissue compared with levels in tumor tissue samples, and this difference gradually increased with higher histological grade and more advanced hepatocellular tumors [39].”
BackgroundRetractedBataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266 · cited 1×
“In a multicenter randomized placebo-controlled trial involving 651 patients with HBV cirrhosis [27], lamivudine decreased the risk of severe liver complications (7.”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310 · cited 6×
“The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action (inactive macrophage Ly6Clow) [6,23].”
BackgroundInfluentialRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Research works printed but not linked: 6
- Cabezas, 2017, Impact of SVR in the development of all complications and fibrosis regression in a cohort of patients treated with interferon-base Triple Therapy and Direct Acting Antiviral, Hepatology, 66, 218A
- Bosch, 2015, Correlation between noninvasive markers of fibrosis and the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), Hepatology, 62, 120A
- Afdha, 2015, Serum lysyl oxidase-like-2 (sLOXL2) is correlated with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis due to hepatitis C, Hepatology, 62, 121A
- Bourliere, 2015, Changes in liver stiffness by transient elastography (TE) and serum lysyl oxidase-like-2 (sLOXL2) in patients with cirrhosis treated with ledipasvir/sofosbuvir (LDV/SOF)-based therapy, Hepatology, 62, 123A
- Puente, 2019, Influence of the metabolic syndrome on fibrosis regression regulated by LOXL2 after sustained virologycal response, Gastroenterol. Hepatol., 42, 123
- Tatal, 2013, Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase like 2, appears safe and well tolerated in patients with liver disease of diverse etiology, J. Hepatol., 58, S409
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“For example, LOX enzymes are widely used to block collagen crosslinking in various preclinical settings [130, 131] .”
BackgroundLysyl oxidases: from enzyme activity to extracellular matrix cross-links
Vallet, S. D., & Ricard-Blum, S. (2019) · Essays in Biochemistry · doi:10.1042/ebc20180050 · Cited by 335
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
“ECM synthesis and degradation, and activities of ECM stabilizing cross-linking enzymes, increase with accumulation of fi broblasts and myo fi broblasts, and progression of fi brotic disease [37 – 39].”
BackgroundChen, W., Yang, A., Jia, J., Popov, Y. V., Schuppan, D., & You, H. (2020) · Hepatology · doi:10.1002/hep.31236 · Cited by 284
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma
Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 141
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 146
“SIM is a monoclonal antibody targeting the lysyl oxidase-like 2 (LOXL2) enzyme that catalyzes the crosslinkage of collagen and elastin, leading to remodeling of the extracellular matrix [186,187].”
BackgroundThe Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Matrix-producing neutrophils populate and shield the skin
Vicanolo, T., Özcan, A., Li, J. L. Y., Huerta-López, C., Ballesteros, I., Rubio-Ponce, A., Dumitru, A. C., Nicolás-Ávila, J. Á., Molina-Moreno, M., Reyes‐Gutierrez, P., et al. (2025) · Nature · doi:10.1038/s41586-025-08741-5 · Cited by 103
“…a wealth of other immune programs across barrier tissues, including the specification of alveolar macrophages in the lungs, Langerhans cells in the skin and IL-17-producing T cells in the gut 28–30 , suggesting that neutrophils are part of a larger, coordinated immune program in border regions.”
The functional and evolutionary impacts of human-specific deletions in conserved elements
Xue, J. R., Mackay-Smith, A., Mouri, K., Garcia, M. F., Dong, M. X., Akers, J. F., Noble, M., Li, X., Zoonomia Consortium†, Lindblad-Toh, K., et al. (2023) · Science · doi:10.1126/science.abn2253 · Cited by 75
“We also investigated one of the strongest species-specific effects in our screen at the lysyl oxidase gene LOXL2 , which maintains the extracellular matrix ( 27 ).”
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 76
Interplay Between LOX Enzymes and Integrins in the Tumor Microenvironment
Amendola, P. G., Reuten, R., & Erler, J. T. (2019) · Cancers · doi:10.3390/cancers11050729 · Cited by 82
“Redundancy in other pathways that mediate collagen crosslinking, including other LOX enzymes, may also explain why simtuzumab was ineffective in clinical trials [145].”
BackgroundExploring Extracellular Matrix Crosslinking as a Therapeutic Approach to Fibrosis
Lloyd, S. M., & He, Y. (2024) · Cells · doi:10.3390/cells13050438 · Cited by 61
“LOX activity is a critical element in fibrosis and is being investigated as a target for therapeutics [15,47,48].”
BackgroundFindlay, A. D., Foot, J. S., Buson, A., Deodhar, M., Jarnicki, A., Hansbro, P. M., Liu, G., Schilter, H. C., Turner, C. I., Zhou, W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01283 · Cited by 61
Assessment of liver fibrosis progression and regression by a serological collagen turnover profile
Karsdal, M. A., Hjuler, S. T., Luo, Y., Rasmussen, D. G. K., Nielsen, M. J., Holm Nielsen, S., Leeming, D. J., Goodman, Z., Arch, R. H., Patel, K., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2018 · Cited by 56
Enzymatic cross-linking of collagens in organ fibrosis – resolution and assessment
Pehrsson, M., Mortensen, J. H., Manon‐Jensen, T., Bay‐Jensen, A., Karsdal, M. A., & Davies, M. J. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1962711 · Cited by 57
LOXL2 in Cancer: A Two-Decade Perspective
Cano, A., Eraso, P., Mazón, M. J., & Portillo, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814405 · Cited by 46
Regression of portal hypertension: underlying mechanisms and therapeutic strategies
Selicean, S. E., Wang, C., Guixé‐Muntet, S., Ştefănescu, H., Kawada, N., & Gracia‐Sancho, J. (2021) · Hepatology International · doi:10.1007/s12072-021-10135-4 · Cited by 44
“In murine models, enzymes such as tissue-transglutaminase (tTG) and lysil oxidases (LOX) induce the cross-linking of collagens and elastins, creating acellular areas that are resistant to degradation [14, 55, 56].”
BackgroundLinking LOXL2 to Cardiac Interstitial Fibrosis
Erasmus, M., Samodien, E., Lecour, S., Cour, M., Lorenzo, Ó., Dludla, P. V., Pheiffer, C., & Johnson, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165913 · Cited by 39
“It is known that under conditions of stress, such as inflammation, LOXL2 expression is induced, and its secretion into the extracellular space is increased [66].”
BackgroundLysyl oxidase like-2 in fibrosis and cardiovascular disease
Poe, A., Yus, M. M., Wang, H., & Santhanam, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00176.2023 · Cited by 43
The Interactome of Cancer-Related Lysyl Oxidase and Lysyl Oxidase-Like Proteins
Vallet, S. D., Berthollier, C., Salza, R., Muller, L., & Ricard‐Blum, S. (2020) · Cancers · doi:10.3390/cancers13010071 · Cited by 37
Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling
Ramis, J., Middlewick, R., Pappalardo, F., Cairns, J. T., Stewart, I. D., John, A. E., Naveed, S.-U. N., Krishnan, R., Miller, S., Shaw, D. E., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.04361-2020 · Cited by 32
“LOXL2 is increased in several diseases associated with tissue remodelling [13 – 17, 46 ], but the We acknowledge that changes in LOXL2 expression do not necessarily lead to changes in enzymatic activity; however, there is currently no commercially available assay to measure LOXL2 activity.”
Jacob, H. K. C., Signorelli, R., Richard, J. L. C., Kashuv, T., Lavania, S., Middleton, A. N., Gomez, B. A., Ferrantella, A. R., Amirian, H., Tao, J., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02425-y · Cited by 31
“Lysyl oxidase homolog 2 (Loxl2) The LOXL family is composed of 5 protein isoforms (LOX and LOXL1-4) that are synthesized as inactive protoenzymes into the extracellular environment and subsequently cleaved into their active form [35], however, our analysis was only focused on the Loxl2 isoform.”
BackgroundHsieh, S., Shen, C., Liao, H., Chen, M., Wu, C.-H., Li, K., Lu, C.-S., Kuo, Y., Tsai, H., Tsai, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145082 · Cited by 28
Pehrsson, M., Manon‐Jensen, T., Sun, S., Villesen, I. F., Castañé, H., Joven, J., Patel, K., Goodman, Z. D., Nielsen, M. J., Bay‐Jensen, A., et al. (2022) · Liver International · doi:10.1111/liv.15270 · Cited by 28
Selective depletion of hepatic stellate cells‐specific LOXL1 alleviates liver fibrosis
Yang, A., Yan, X., Xu, H., Fan, X., Zhang, M., Huang, T., Li, W., Chen, W., Jia, J., & You, H. (2021) · The FASEB Journal · doi:10.1096/fj.202100374r · Cited by 27
Lysyl Oxidase Like‐2 (LOXL2): An Emerging Oncology Target
Chopra, V., Sangarappillai, R. M., Romero‐Canelón, I., & Jones, A. M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900119 · Cited by 27
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., Li, Y., Zhou, K., Yu, X., Yang, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147841 · Cited by 27
An in situ activity assay for lysyl oxidases
Wang, H., Poe, A., Pak, L., Nandakumar, K., Jandu, S., Steppan, J., Löser, R., & Santhanam, L. (2021) · Communications Biology · doi:10.1038/s42003-021-02354-0 · Cited by 26
Sepúlveda‐Crespo, D., Resino, S., & Martínez, I. (2021) · Drugs · doi:10.1007/s40265-020-01458-x · Cited by 24
The Expression Patterns and Roles of Lysyl Oxidases in Aortic Dissection
Yi, X., Zhou, Y., Chen, Y., Feng, X., Liu, C., Jiang, D., Geng, J., Li, X., Jiang, X., & Fang, Z. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.692856 · Cited by 23
“reported that chronic inflammation could induce LOXL2 expression and extracellular secretion in the liver (35, 36).”
BackgroundInnovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes
Sah, A. K., Afzal, M., Elshaikh, R. H., Abbas, A. M., Shalabi, M. G., Prabhakar, P. K., Babker, A. M. A., Khalimova, F., Sabrievna, V. A., & Choudhary, R. K. (2025) · Life · doi:10.3390/life15050779 · Cited by 22
“In addition, inhibitors of lysyl oxidase-like 2 (LOXL2) and integrins are currently being investigated for their antifibrotic effects in cirrhosis [68].”
Lysyl oxidase-like 2 processing by factor Xa modulates its activity and substrate preference
Wang, H., Poe, A., Yus, M. M., Pak, L., Nandakumar, K., & Santhanam, L. (2023) · Communications Biology · doi:10.1038/s42003-023-04748-8 · Cited by 20
Extracellular Targets to Reduce Excessive Scarring in Response to Tissue Injury
Fertala, J., Wang, M. L., Rivlin, M. R., Beredjiklian, P. K., Abboud, J. A., Arnold, W. V., & Fertala, A. (2023) · Biomolecules · doi:10.3390/biom13050758 · Cited by 21
Kuykendall, A. T., Horvat, N. P., Pandey, G., Komrokji, R. S., & Reuther, G. W. (2020) · Cancers · doi:10.3390/cancers12082278 · Cited by 18
Gao, A. Y., Espinosa, A. M. D., Nguyen, B. B. N., Link, P. A., Meridew, J. A., Jones, D. L., Gibbard, D. F., Tschumperlin, D. J., & Haak, A. J. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001442 · Cited by 16
“LOXL2-A New Target in Antifibrogenic Therapy?”
InfluentialEspíndola, M. S., Habiel, D. M., Coelho, A. L., Parimon, T., Chen, P., Mikels, A. J., & Hogaboam, C. M. (2023) · Fibrosis · doi:10.35534/fibrosis.2023.10007 · Cited by 18
Liu, X., Ma, H., Wu, R., Wang, H., Xu, H., Li, S., Wang, G., Lv, G., & Niu, J. (2022) · Genes · doi:10.3390/genes13122201 · Cited by 17
“Collectively, 138 DEmiRNAs were potentially bound to 1193 DE genes, which were involved in different types of collagen (COL4A1, COL4A2, COL13A1, COL14A1, COL16A1, and COL26A1), lysyl oxidase-like 2 (LOXL2) [67], platelet-derived growth factor receptor β (PDGFRβ) [68], and other fibrosis-related genes.”
BackgroundSchreyer, E., Obringer, C., Messaddeq, N., Kieffer, B., Zimmet, P., Fleming, G. A., Geberhiwot, T., & Marion, V. (2022) · Diabetes · doi:10.2337/db22-0058 · Cited by 14
Lan, P., Sun, W., Cheng, D., Jia, X., Lian, W., Li, Z., Xiong, H., Wang, T., Liu, Y., & Ni, C. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117572 · Cited by 13
Natural Autoantibodies in Chronic Pulmonary Diseases
Fukushima, K., Tsujino, K., Futami, S., & Kida, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031138 · Cited by 13
“For example, we found that autoAbs against lysyl oxidase-like 2 (LOXL2), an enzyme that promotes crosslinking of extracellular matrix molecules such as collagen and elastin through oxidation, are frequent in INSIP patients.”
BackgroundInfluentialThapa, K., Grewal, A. S., Kanojia, N., Rani, L., Sharma, N., & Singh, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200121143959 · Cited by 14
Buscher, K., Heitplatz, B., Marck, V. V., Song, J., Loismann, S., Rixen, R., Hüchtmann, B., Kurian, S. M., Ehinger, E., Wolf, D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020121685 · Cited by 11
“Due to covalent crosslinking of collagen fibers, LOXL2 plays a critical role in extracellular matrix organization, tissue remodeling, and fibrosis.(44,45) Here, we demonstrate how a novel CD681 macrophage population expressing LOXL2 could be derived from the phenotype framework as a potential biomarker.”
BackgroundRestored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging
Tan, Y. J., Conley, T. E., Yao, F., Garcia-Marques, F. J., Akinyemi, D. E., Dinh, V. V., Wang, Q., Bermudez, A., Kim, J., Belk, J. A., et al. (2026) · Science · doi:10.1126/science.aea3075 · Cited by 11
Human amniotic membrane modulates collagen production and deposition in vitro
Moreno, S. E., Enwerem-Lackland, I., Dreaden, K., Massee, M., Koob, T. J., & Harper, J. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-64364-2 · Cited by 10
SPECT Imaging of Lysyl Oxidase-like 2 in a Model of Idiopathic Pulmonary Fibrosis
Vizier, R., Garnier, A.-R., Dias, A. M. M., Moreau, M., Claron, M., Collin, B., Denat, F., Bellaye, P., & Gonçalves, V. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00232 · Cited by 9
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
“Consequently, LOXL2 inhibition has also become a possible target for liver fibrosis, leading to the development of a monoclo - nal antibody against LOXL2, simtuzumab [109 ].”
Zhang, J., Lu, M., Guan, X., Hao, J., Li, Y., Zhang, L., & Li, C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01312-z · Cited by 8
“LOXL2 can post-transcriptionally modify type I collagen and elastin by transforming peptide lysine and hydrox-ylysine residue in collagen into allysine, which is responsible for forming crosslinks that stabilize collagen and elastin within the ECM [87].”
Mincheva, G., Moreno‐Manzano, V., Felipo, V., & Llansola, M. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123429 · Cited by 8
Puente, Á., Fortea, J. I., Posadas, M., García-Blanco, A., Rasines, L., Cabezas, J., Arias, M., Llerena, S., Iruzubieta, P., Fábrega, E., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081242 · Cited by 7
“The focus on irreversible biochemical changes has allowed for the identification of lysyl oxidase 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix [15,16].”
BackgroundSelf-citationTang, S., & Borlak, J. T. (2024) · Hepatology · doi:10.1097/hep.0000000000000780 · Cited by 9
“[39] Lysyl oxidase-like 2 is regulated in 3% of cases, and its consistent downregulation is counterintuitive given its mode of action.”
Chida, T., Ohta, K., Noritake, H., Matsushita, M., Murohisa, G., Kageyama, F., Sasada, Y., Oyaizu, T., Tsugiki, M., Tamakoshi, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61366-y · Cited by 5
Increased serum LOXL2 concentration in pelvic inflammatory disease with pelvic adhesion
Xie, C., Tang, B., Kunlun, W., Meng, Q., & Fang, W. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01640-1 · Cited by 6
“LOXL2 is involved in fibrogenesis of various diseases, and modulates the process of matrix remodeling and EMT by cross-linking of collagen I [19].”
BackgroundTemporal evolution of fibroblast responses following salivary gland ductal ligation injury
Tavarez, J. R., Kenney, J., Gabunia, S., Nelson, D. A., & Larsen, M. (2025) · Frontiers in Dental Medicine · doi:10.3389/fdmed.2025.1581376 · Cited by 4
Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery
Chaudhary, B., Kumar, P., Arya, P., Singla, D., Kumar, V., Kumar, D., Roshan, S., Wadhwa, S., Gulati, M., Singh, S. K., et al. (2022) · Current Drug Metabolism · doi:10.2174/1389200224666230110145513 · Cited by 5
CELLULAR AND MOLECULAR MECHANISMS OF LIVER FIBROGENESIS
Lebedeva, E. I., & Myadelets, O. D. (2019) · Hepatology and Gastroenterology · doi:10.25298/2616-5546-2019-3-2-119-126 · Cited by 4
Fertala, A. (2026) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-032-05273-5_11 · Cited by 4
Immanuel, J. R., Kumar, R., Agrahari, A. K., & Asthana, S. (2024) · Liver international communications. · doi:10.1002/lci2.85 · Cited by 3
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
Kaur, J., Singh, P., Enzler, T., & Sahai, V. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1905795 · Cited by 3
“LOXL-2 is one of the five variants of the lysyl oxidase (LOX) gene family, which is overexpressed in PDAC and involved in EMT and metastasis [119,120].”
BackgroundMechanical network motifs as targets for mechanomedicine
Lu, M., Zhao, X., Xu, F., Yin, C., Guo, H., & Cheng, B. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104145 · Cited by 3
MicroRNA‐29b attenuates fibrosis in a rat model of Peyronie's disease
Candido, P., Pimenta, R., Maluf, F. C., Chiovatto, C., Romão, P., Baldavira, C. M., Ghazarian, V., de Camargo, J. A., Guimarães, V., dos Santos, G. A., et al. (2024) · Andrology · doi:10.1111/andr.13672 · Cited by 2
Prognostic significance of LOXL2 enzyme activity in primary myelofibrosis
Lv, G., & Lv, W. (2024) · Medicine · doi:10.1097/md.0000000000040924 · Cited by 2
Kaur, K. K., Allahbadia, G., & Singh, M. (2021) · Journal of Endocrinology Research · doi:10.30564/jer.v3i2.3520 · Cited by 6
Cell–matrix interactions, force transmission, and mechanosensation
Walter, C., Zmuda, H. M., Almeida, J. A., & Pathak, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90195-6.00020-6 · Cited by 2
Serum levels of lysyl oxidase-like 2 are increased in patients with dermatomyositis
Yang, M., Chen, Y., Lin, S., Liu, H., & Xie, Q. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/jikxzi · Cited by 2
Nakase, H., & Ishigami, K. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.004 · Cited by 2
Arthrofibrosis of the elbow joint: mechanisms and factors of development
Egiazaryan, K. A., Lazishvili, G. D., Ratyev, A. P., Badriev, D. A., Жаворонков, Е. А., & Lidyaev, A. A. (2023) · Surgical practice (Russia) · doi:10.38181/2223-2427-2023-1-7 · Cited by 2
Xie, C., Chen, Y., Wang, F., Zhu, H., Ma, H., & Tang, B. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.754 · Cited by 1
Caon, E., Forlano, R., Mullish, B. H., Manousou, P., & Rombouts, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00025-5 · Cited by 1
Radić, M., Belančić, A., Vučković, M., Fajkić, A., Rogoznica, M., & Radić, J. (2025) · Biomedicines · doi:10.3390/biomedicines13122932 · Cited by 1
“Inhibition of LOXL2, a key enzyme in collagen cross-linking, is also under investigation [90].”
Guo, C., Pan, Q., & Ma, X. (2022) · Open Medicine · doi:10.1515/med-2022-0460 · Cited by 1
“, proliferation, apoptosis, migration, and contraction), which are largely based on interactions between collagen and cell adhesion molecules [16].”
BackgroundNavigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis
Pham, H. N., Pham, L., & Sato, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362263 · Cited by 1
“…to assess the efficacy and safety of CM-101 therapy at doses of 10 or 20 mg/kg. Liver fibrosis is induced by robust accumulation of extra-cellular matrix proteins, such as collagens, and lysyl oxidase-like 2 (LOXL2) promotes crosslinking of collagen fibers contributing to fibrogenesis [116].”
BackgroundMechanotherapeutics for the Treatment of Idiopathic Pulmonary Fibrosis
Lagares, D., & Han, H. (2021) · Barcelona Respiratory Network · doi:10.23866/brnrev:2020-0012
Avaliação do papel terapêutico do microRNA-29b em um modelo pré-clínico da doença de Peyronie
Cândido, P. R. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-20042023-120958
Jacob, H. K. C., Signorelli, R., Richard, J. L. C., Kashuv, T., Lavania, S., Middleton, A. N., Gomez, B. A., Ferrantella, A. R., Amirian, H., Tao, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20626352
Li, H., Li, Q., Chen, X., Mo, L., Wang, Y., Liu, X., Wang, X., Qu, Z., Wang, J., & Li, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s561740
“51,52 Moreover, solely inhibiting LOXL2 may lead to compensatory upregulation of other LOX family members, potentially affecting therapeutic efficacy.”
InfluentialBindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Metadata
- Authors
- Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J.
- Affiliations
- Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain
- Universidad de Cantabria (ES)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-02
- Volume
- 20
- Issue
- 7
- Pages
- 1634
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6480111
- OpenAlex
- W2933665664
- Cited by
- 79
- References
- 58
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 14 · 2020: 13 · 2019: 6
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCrea (University of Cantabria) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- LOXL2, liver fibrosis, antifibrotic therapy, liver cirrhosis, extracellular matrix, collagen deposition, hepatic stellate cells, Kupffer cells, monoclonal antibodies, fibrosis reversibility, portal pressure
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Protein-Lysine 6-Oxidase, Models, Biological, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.